Duniya SanoStem Inc Acquires Stemedica Cell Technologies, Inc.
Bakersfield, CA – February 4, 2025 – Duniya SanoStem Inc (SanoStem), a global biotechnology company, is pleased to announce the full acquisition of Stemedica Cell Technologies, Inc., a government-licensed cGMP manufacturer of best-in-class Allogeneic (Donor) Adult Stem Cells and Stem Cell Factors.
Stemedica ‘s clinical-grade Ischemic Tolerant (Low Oxygen) mesenchymal stem cells (itMSC) are being used in FDA-approved Investigational New Drug (IND) applications for Acute Myocardial Infarction, Chronic Heart Failure, Cutaneous Photoaging, Ischemic Stroke, Traumatic Brain Injury, and Alzheimer’s Disease.
With this acquisition, SanoStem intends to aggressively pursue the FDA-approved Phase IIb/III clinical trial in chronic ischemic stroke across multiple countries using these Unique Patented Immune Privileged (No Transfusion Reactions), Ready-To-Treat MSC, now branded as SanoMSC.